Strides Pharma Science Reports Strong FY26 Performance with EBITDA at ₹9,253m
Strides Pharma Science Limited announced its consolidated financial results for the quarter (Q4FY26) and Full Year (FY26) ended March 31, 2026, reflecting significant growth driven by its Ex-US markets. The company also recommended a dividend of ₹ 5 per share per share.The results showed strong performance across profitability, efficiency, and growth metrics.
FY26 Performance Overview
The company reported key operational and financial metrics for FY26:- Ex-US Market Revenue: The Ex-US market generated ₹ 22,404m ($254m), recording a strong growth of 21% Year over Year (YoY).
- US Market Revenue: Revenue from the US market reached ₹ 24,897m ($284m), growing 2% YoY.
- Profitability Metrics:
* Operational EPS stood at ₹ 56.2.
* Efficiency Improvement:
* The Net Debt to EBITDA ratio improved significantly to 1.55x in FY26, down from 1.9x in FY25.
* Return on Capital Employed (RoCE) increased to 15.8% in FY26, up from 14.9% in FY25.
* Debt Impact: Reported Net Debt stood at ₹14,365m, which was impacted by a Foreign Exchange (Fx) depreciation of ₹ 1,115m.
Financial Results Summary
The full set of consolidated financial results highlights the following figures (in ₹ m):| Particulars | Q4FY26 | Q4FY25 | YoY | Q3FY26 | QoQ | FY26 | FY25 | YoY |
|---|---|---|---|---|---|---|---|---|
| Revenue | 13,235 | 11,904 | 11.2% | 11,946 | 10.8% | 48,587 | 45,653 | 6.4% |
| Gross Margin | 7,872 | 6,914 | 13.9% | 7,317 | 7.6% | 29,000 | 25,854 | 12.2% |
| Gross Margin% | 59.5% | 58.1% | 140bps | 61.2% | -170bps | 59.7% | 56.6% | 310bps |
| EBITDA | 2,397 | 2,179 | 10.0% | 2,359 | 1.6% | 9,253 | 8,208 | 15.3% |
| EBITDA% | 18.1% | 18.3% | -20bps | 19.8% | -170bps | 19.0% | 17.6% | 140bps |
| Operational PAT | 1,357 | 1,130 | 20.0% | 1,282 | 5.9% | 5,181 | 3,447 | 50.3% |
| Operational EPS ( ₹ ) | 14.7 | 12.3 | 20.0% | 13.9 | 5.8% | 56.2 | 37.5 | 50.1% |
| Reported PAT | 1,293 | 856 | 51.0% | 2,081 | -37.9% | 5,745 | 4,094 | 40.3% |
| Reported EPS ( ₹ ) | 13.8 | 8.9 | 54.3% | 21.9 | -37.2% | 60.3 | 44.0 | 37.0% |
Note: Operational PAT excludes exceptional items and one time income.
Management Commentary
Badree Komandur, Managing Director & Group CEO, stated that Strides continued to deliver strong performance across profitability, efficiency, and growth metrics during FY26. He attributed this strength primarily to the Ex-US markets, which recorded a growth of 21% YoY.Komandur noted that the company’s focus on profitability drove gross margin expansion of 310bps YoY and EBITDA margin improvement of 140bps YoY to 19%. Operational PAT and EPS grew by 50% YoY, reflecting strong operating leverage. He highlighted that the US business remained stable during the year, though impacted by a weaker flu season in the second half. Despite ongoing geopolitical uncertainties, the company remains committed to delivering long term sustainable and profitable growth.
STAR Stock Price Movement
Strides Pharma Science Limited shares today slipped by 1.87% to settle at ₹1132.10. The equity traded on a volume of 1.01 million shares, holding above its intraday low of ₹1115.Disclaimer: Due care and diligence have been taken in compiling and presenting news and market-related content. However, errors or omissions may arise despite such efforts.
The information provided is for general informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any securities. Readers are advised to rely on their own assessment and judgment and consult appropriate financial advisers, if required, before taking any investment-related decisions.
Any views, opinions, or statements expressed, where applicable, are those of the respective analysts or experts and do not reflect the views of this website. The website has no association with such viewpoints and does not assume any responsibility for them.